OKYO Relative Valuation
OKYO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OKYO is overvalued; if below, it's undervalued.
Historical Valuation
OKYO Pharma Ltd (OKYO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.71. The fair price of OKYO Pharma Ltd (OKYO) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.25
Fair
-10.45
PE
1Y
3Y
5Y
0.00
EV/EBITDA
OKYO Pharma Ltd. (OKYO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.18. The thresholds are as follows: Strongly Undervalued below -9.93, Undervalued between -9.93 and -5.05, Fairly Valued between 4.70 and -5.05, Overvalued between 4.70 and 9.58, and Strongly Overvalued above 9.58. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-8.63
EV/EBIT
OKYO Pharma Ltd. (OKYO) has a current EV/EBIT of -8.63. The 5-year average EV/EBIT is -5.16. The thresholds are as follows: Strongly Undervalued below -12.13, Undervalued between -12.13 and -8.65, Fairly Valued between -1.67 and -8.65, Overvalued between -1.67 and 1.81, and Strongly Overvalued above 1.81. The current Forward EV/EBIT of -8.63 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
OKYO Pharma Ltd. (OKYO) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-9.75
P/OCF
OKYO Pharma Ltd. (OKYO) has a current P/OCF of -9.75. The 5-year average P/OCF is -2.96. The thresholds are as follows: Strongly Undervalued below -8.95, Undervalued between -8.95 and -5.95, Fairly Valued between 0.03 and -5.95, Overvalued between 0.03 and 3.03, and Strongly Overvalued above 3.03. The current Forward P/OCF of -9.75 falls within the Strongly Undervalued range.
-7.91
P/FCF
OKYO Pharma Ltd. (OKYO) has a current P/FCF of -7.91. The 5-year average P/FCF is -1.89. The thresholds are as follows: Strongly Undervalued below -16.13, Undervalued between -16.13 and -9.01, Fairly Valued between 5.23 and -9.01, Overvalued between 5.23 and 12.35, and Strongly Overvalued above 12.35. The current Forward P/FCF of -7.91 falls within the Historic Trend Line -Fairly Valued range.
OKYO Pharma Ltd (OKYO) has a current Price-to-Book (P/B) ratio of -14.47. Compared to its 3-year average P/B ratio of -13.02 , the current P/B ratio is approximately 11.17% higher. Relative to its 5-year average P/B ratio of -11.03, the current P/B ratio is about 31.24% higher. OKYO Pharma Ltd (OKYO) has a Forward Free Cash Flow (FCF) yield of approximately -2.16%. Compared to its 3-year average FCF yield of -14.49%, the current FCF yield is approximately -85.09% lower. Relative to its 5-year average FCF yield of -13.81% , the current FCF yield is about -84.35% lower.
-14.47
P/B
Median3y
-13.02
Median5y
-11.03
-2.16
FCF Yield
Median3y
-14.49
Median5y
-13.81
Competitors Valuation Multiple
The average P/S ratio for OKYO's competitors is -173.03, providing a benchmark for relative valuation. OKYO Pharma Ltd Corp (OKYO) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OKYO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OKYO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is OKYO Pharma Ltd (OKYO) currently overvalued or undervalued?
OKYO Pharma Ltd (OKYO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.71. The fair price of OKYO Pharma Ltd (OKYO) is between to according to relative valuation methord.
What is OKYO Pharma Ltd (OKYO) fair value?
OKYO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of OKYO Pharma Ltd (OKYO) is between to according to relative valuation methord.
How does OKYO's valuation metrics compare to the industry average?
The average P/S ratio for OKYO's competitors is -173.03, providing a benchmark for relative valuation. OKYO Pharma Ltd Corp (OKYO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for OKYO Pharma Ltd (OKYO) as of Jan 08 2026?
As of Jan 08 2026, OKYO Pharma Ltd (OKYO) has a P/B ratio of -14.47. This indicates that the market values OKYO at -14.47 times its book value.
What is the current FCF Yield for OKYO Pharma Ltd (OKYO) as of Jan 08 2026?
As of Jan 08 2026, OKYO Pharma Ltd (OKYO) has a FCF Yield of -2.16%. This means that for every dollar of OKYO Pharma Ltd’s market capitalization, the company generates -2.16 cents in free cash flow.
What is the current Forward P/E ratio for OKYO Pharma Ltd (OKYO) as of Jan 08 2026?
As of Jan 08 2026, OKYO Pharma Ltd (OKYO) has a Forward P/E ratio of -10.45. This means the market is willing to pay $-10.45 for every dollar of OKYO Pharma Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for OKYO Pharma Ltd (OKYO) as of Jan 08 2026?
As of Jan 08 2026, OKYO Pharma Ltd (OKYO) has a Forward P/S ratio of 0.00. This means the market is valuing OKYO at $0.00 for every dollar of expected revenue over the next 12 months.